Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 52 week low

<< Previous

Bullboard Posts

Next >>

Comment by baggerx99on Jul 18, 2021 10:18am

144 Views

Post# 33566642

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:52 week low

Hey all, will all know the naysayers are solely interested in sending the SP lower and lower for additional accumulation. They know the full potential of ATE too. With all the brain pwer in ATE, from the board, scientific, clinical and partnering advisories, and mgmt, ATE shareholders are in superb hands and despite off the wall comments by a few BB naysayers. Be assured mgmt decisions are well strategized by all, with the many years of industry experience. Success in Otena and pipeline drugs will not be determined by daily SP performance but by what is happening at the boardroom table that will be shared at some point down the road. Thanks to Mugs, Marky, and others that keep the boat on course by reminding the forum of progress to date, and catalysts forthcoming and eventually holders of the gold medal. Cheers!

JimmyJ wrote:

MrMugsy wrote:

JimmyJ wrote:

Doccole wrote:
I don't mind him as a person, prolly a great guy. I don't like how this strategy has unfolded. I am not sure what is up for vote, haven't looked yet, but I will be saying no to any "atta boy" shares and no to things I don't endorse.

Where do you think the SP would today if the Connacord raise didn't happen back February following the Nuance deal?

We'll never know but based on historical data in this industry, it would gone up maybe to $8 or $10 max, followed by a slow bleed back to these levels guaranteed. When catalysts are 6-8 months apart, these stocks always drop. It's the nature of biotech. It's a damned if you do, more damned if you don't situation for Dan. He had an opportunity to increase the cash reserve with little impact knowing exactly where the SP was going in the long run this year. It was the right call IMO.

As sad as it is, this won't be the last time we see a major claw back with this stock. There will likely be many more before they hit it out of the park. It's going to be a bumpy ride to get there. Sit back, buckle up and enjoy.

Well said Jimmy.
Ya - lots of up and down stock price play for those that remain shareholders ... I'm sure.
Hopefully hitting higher highs and higher lows along the way forward.

Agreed. Higher low's will come after meeting significant milestone and higher "sustainable" high's will come when real dollars come through the door; either from licensing, a buyout or manufacturing.

There is a laundry list of good things done recently that has set the stage for hopefully even better things to come.

As much as people don't like it or Dan, I don't see it making a big difference in a vote. The board and the big players are looking towards the future with this play and it's looking like it's tee'd up nicely for success. Time will tell.